GOSS Stock - Gossamer Bio, Inc.
Unlock GoAI Insights for GOSS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $114.70M | N/A | N/A | N/A | N/A |
| Gross Profit | $114.70M | N/A | N/A | N/A | $-4,268,000 |
| Gross Margin | 100.0% | N/A | N/A | N/A | N/A |
| Operating Income | $-59,919,000 | $-183,759,000 | $-218,593,000 | $-216,124,000 | $-210,582,000 |
| Net Income | $-56,528,000 | $-179,817,000 | $-229,378,000 | $-234,004,000 | $-243,360,000 |
| Net Margin | -49.3% | N/A | N/A | N/A | N/A |
| EPS | $-0.25 | $-0.80 | $-2.84 | $-3.33 | $-3.67 |
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
Visit WebsiteEarnings History & Surprises
GOSSEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q1 2026 | Mar 12, 2026 | $-0.19 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.19 | $-0.21 | -10.5% | ✗ MISS |
Q3 2025 | Aug 5, 2025 | $-0.18 | $-0.17 | +5.6% | ✓ BEAT |
Q2 2025 | May 15, 2025 | $-0.18 | $-0.16 | +11.1% | ✓ BEAT |
Q1 2025 | Mar 13, 2025 | $-0.17 | $-0.15 | +11.8% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.18 | $-0.14 | +22.2% | ✓ BEAT |
Q3 2024 | Aug 12, 2024 | $0.23 | $0.22 | -4.3% | ✗ MISS |
Q2 2024 | May 7, 2024 | $-0.19 | $-0.19 | 0.0% | = MET |
Q1 2024 | Mar 5, 2024 | $-0.20 | $-0.21 | -5.0% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.20 | $-0.21 | -5.0% | ✗ MISS |
Q3 2023 | Aug 8, 2023 | $-0.49 | $-0.45 | +8.2% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.55 | $-0.52 | +5.5% | ✓ BEAT |
Q1 2023 | Mar 17, 2023 | $-0.62 | $-0.59 | +4.8% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-0.66 | $-0.65 | +1.5% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-0.67 | $-0.74 | -10.4% | ✗ MISS |
Q2 2022 | May 10, 2022 | $-0.77 | $-0.76 | +1.3% | ✓ BEAT |
Q1 2022 | Mar 3, 2022 | $-0.74 | $-0.74 | 0.0% | = MET |
Q4 2021 | Nov 8, 2021 | $-0.78 | $-0.80 | -2.6% | ✗ MISS |
Q3 2021 | Aug 9, 2021 | $-0.77 | $-0.80 | -3.9% | ✗ MISS |
Latest News
Frequently Asked Questions about GOSS
What is GOSS's current stock price?
What is the analyst price target for GOSS?
What sector is Gossamer Bio, Inc. in?
What is GOSS's market cap?
Does GOSS pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to GOSS for comparison